Edition:
United States

Galapagos FY Revenue Up At 317.8 Million Euros


Friday, 22 Feb 2019 02:10am EST 

Feb 22 (Reuters) - GALAPAGOS NV ::SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO.FY OPERATING LOSS EUR 44.8 MLN VS LOSS OF EUR 89.8 MLN YR AGO.FY NET LOSS EUR 29.3 MLN VS LOSS OF EUR 115.7 MLN YR AGO.CASH, CASH EQUIVALENTS AND RESTRICTED CASH EUR 1.29 BLN AT END-2018 VS EUR 1.15 BLN YR AGO.EXPECTS TO RUN OVER 40 CLINICAL TRIALS THIS YEAR.WE WILL EXPAND OUR COMMERCIAL ORGANIZATION FURTHER AS WE GEAR UP FOR A POTENTIAL MARKET LAUNCH OF FILGOTINIB IN 2020 -CFO.IN 2019 AIMS TO REPORT TOPLINE RESULTS FOR THE FINCH 1 AND FINCH 3 TRIALS IN RA IN Q1.IN 2019 PLANS TO FULLY RECRUIT OUR PHASE 2 PINTA STUDY FOR OUR FULLY PROPRIETARY IPF COMPOUND GLPG1205 AS WELL AS OUR ROCCELLA STUDY IN OA.FOR MOR106 WE PLAN TO START A PHASE 2 TRIAL IN ATD WITH MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS.IN H2 2019 EXPECT PRIMARY ANALYSIS OF THE IGUANA PHASE 2 TRIAL IN ATD AND TOPLINE RESULTS OF SUBCUTANEOUS PHASE 1 BRIDGING STUDY.WE EXPECT AN OPERATIONAL CASH BURN BETWEEN €320 AND €340 MILLION IN 2019.